

Wanbury Infotech Pvt. Ltd.

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
Fax : +91-22-6794 2111/333
Website : www.wanbury.com



July 01, 2026

To BSE Limited PJ. Towers, Dalal Street Mumbai - 400 001. Script Code: 524212	To National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Script Code: WANBURY
---	--

Dear Sir/Madam,

Sub.:Disclosure under Regulation 30 of the SEBI LODR, 2015 - Investors Presentation on Q4 & Year ended 31.03.2026

As per Regulation 30 of SEBI LODR, 2015, please find attached herewith copy of Investors Presentation on Audited Financial Results (AFR) for the quarter and year ended 31st March, 2026 and is also available on the website of the Company at www.wanbury.com

This is for your information and record.

Thanking you.

Yours faithfully,
For Wanbury Limited



Jitendra J. Gandhi
Company Secretary

Encl.: a/a.



Towards Better Healthcare

Towards Better Healthcare

Earnings Presentation

Q4 & FY26 | July 2026

Wanbury Limited

NSE: WANBURY | BSE: 524212

Bloomberg: WANB:IN



Inside this Presentation

Company Profile



Executive Summary	04
Corporate Journey	05
Successful Business Turnaround	06
Wanbury at a Glance	07
Business Streams	08
Board of Directors	09
Senior Leadership	10
R&D Capabilities	11
Environment, Health & Safety	12

Business Profile



API Business	
Strategically Curated Product Portfolio	14
World-Class Manufacturing Infrastructure	15
Developed Market Focused Business Profile	15
Regulatory Approvals	16
Manufacturing Capabilities	17
Strategy & Way Forward	18
Safety First Culture	19



Formulations Business	
Re-Building Business	22
Brand Portfolio	23
Strategy & Way Forward	24

Q4 & FY26 Earnings Update



Performance Highlights	26
Business Verticals Performance	27
P&L Snapshot	28
Management Commentary	29

Financial Profile



Key Performance Indicators	31
5Y P&L Snapshot	32
5Y Balance Sheet Snapshot	33
5Y Cash Flow Snapshot	34
Capital Markets Overview	35

01


Company Profile

Executive Summary	04
Corporate Journey	05
Successful Business Turnaround	06
Wanbury at a Glance	07
Business Streams	08
Board of Directors	09
Senior Leadership	10
R&D Capabilities	11
Environment, Health & Safety	12




Executive Summary

Successful turnaround to growth momentum



Operational & financial turnaround over last 3 years, now transforming into growth momentum

Global market leaderships in key products



Globally significant market share in Metformin & Sertraline

Building new growth drivers in API business



Through launch of an Anaesthetic in Q4FY26, and pipeline of 4 molecules commercialisation each year beginning current financial year

De-risked & robust balance sheet



Refinanced debt & healthy internal accruals i.e. moderate leverage ratio of ~2X Debt/EBITDA

Established global regulatory approvals




Levers for operating leverage & margin expansion



Through brownfield expansion, operational scale-up, and borrowing cost optimisation

Formulation growth story



Turnaround, break-even (in FY26), to rebuilding & scale-up (in FY27)

Corporate Journey

1990-2000

Foundation & Early Strategic Acquisitions

1990

Incorporated as Pearl Organics Pvt. Ltd.

1992

Established 1st plant for manufacturing APIs

1995

Acquired Brij Chemicals' plant at Patalganga (Maharashtra)

1995

Acquired Wander Limited → a subsidiary of Sandoz (Brand Formulation Business)

1996

Formed a strategic alliance with Wyckoff Chemicals (US) to market APIs in US

2000-2010

Corporate Consolidation & Venture into Developed Markets

2002

USFDA approval received for Patalganga plant

2004

Wander Limited merged with Pearl Organics Limited → Renamed Wanbury Limited

2006

Acquired Doctor's Organic and Chemicals Limited (DOCL) with a multi-purpose USFDA-approved facility in Tanuku

2007

- DOCL merged with Wanbury Limited
- Listing on NSE & BSE
- Acquired Cantabria Pharma S.L. (Spain) - Present in ethical branded formulations in European market

2010-2023

Challenges & Business Turnaround

Underwent Corporate Debt Restructuring with Banks

2020

Deleveraged through strategic sale of brands to Cipla worth ₹87 crore

2021

Capital infusion of ₹50 crore through Preferential Issue

2023

- Raised ₹95 crore via NCD from Neo AIF
- Settlement with all the lenders

2024-Onwards

Transformation & Growth

2024

Scale up EBITDA to ₹73 crore

2025

- Modernised the facilities with an investment of ₹48 crore
- 6th successful USFDA inspection for Patalganga plant (zero 483 observations)
- Successful ANVISA audit clearance for Tanuku plant
- Refinanced Neo AIF Debt at lower interest rate

2026

- Achieved highest-ever Operational EBITDA of ₹108 crore

Successful Business Turnaround

Financial Turnaround



Debt reduction: **~75% reduction from peak-debt obligation of ~700 Crores**, including corporate guarantee from Wanbury Limited to Wanbury Holding B.V. (Netherlands) for foreign debt held by Netherlands subsidiary



Debt refinancing: **Reduction in borrowing cost from 22.5% to 12.5% with effected from 1st March 2025**, with scope for further reduction in coming years



Exited all high cost private financial agreements

Operational Turnaround



Capacity ramp-up in key existing API products through de-bottlenecking:
Metformin (25% increase in last 3 years)
& Sertraline (20% increase in last 3 years)



Operational profitability: **~4X EBITDA scale-up between FY23-FY26**, through de-bottlenecking projects & production scale-up, efficient procurement practises, technical savings, among others





Envisaged break-even profitability in Formulations business, delivered financial break-even in FY26

Wanbury at a Glance

 **6 products,
100% chronic
portfolio**
API Portfolio

 **10+ brands,
acute &
semi-chronic**
Formulations Portfolio

 **2 USFDA
approved API
facilities**
with 386 KL cumulative
reactor capacity

 **80%+**
Export top line, with
emphasis on developed
markets



 **1,200+**
Employee strength

 **37+ years**
Operating history

 **Regulatory
Approvals**



Dual revenue-stream



Business Streams

API



API manufacturer building a niche, profitable & sustainable business (50%+ Gross contribution margins)

Diversified business stream across 6 products + additional launches in pipeline

Regulatory markets focused (EU, Brazil, US) mature & sustainable API business

₹574 Crore

FY26 Revenue

Formulations





Rebuilding legacy brand formulations business in India

10+ active brands + additional launches in pipeline

Key therapeutic categories such as Anti cold & cough, Anti-infective, Anti-inflammatory, Supplements, Orthopaedic, among others

₹76 Crore

FY26 Revenue



Board of Directors



Mr. Mohan Kumar Rayana

Promoter & Whole Time Director

25+ years of experience

He holds a Bachelor of Pharmacy from the University of Mumbai and brings over 25 years of diverse experience in the pharmaceutical industry. He has led the company's growth since inception, overseeing strategic acquisitions and operational expansion.



Mr. K. Chandran

Whole Time Director

30+ years of experience

He graduated with a Bachelor of Science from the University of Mumbai and has over 28 years of pharmaceutical sector experience. Mr. Chandran has played a key role in the company's strategic direction and has been associated with Wanbury for more than 25 years.



Dr. Anupama Vaidya

Non Executive Independent Woman Director

30+ years of experience

She holds a Bachelor's degree in Computer Science from the University of Pune as well as an MBA specializing in Human Resource Development from Symbiosis Institute of Business Management, Pune. She brings a strong background in technology and HR development to the board.



Mr. Mridul Mehta

Non Executive Independent Director

30+ years of experience

He holds a BE in Computer Science from Maharaja Sayajirao University Baroda and an MBA in Finance from the Indian Institute of Management (IIM), Bangalore. With more than 30 years of professional experience, Mr. Mehta specializes in business strategy, management consulting, investment banking, and finance.



Mr. Manoj Gursahani

Non Executive Independent Director

35+ years of experience

He serves as the Executive Director of the Mumbai-Global Chamber and is Co-Founder of Vera Healthcare Technologies, an AI-driven platform for early screening and detection of Diabetic Retinopathy, Glaucoma, and Age-Related Macular Degeneration. He brings significant leadership experience from the healthcare and technology sectors.



Mr. Pallavur Sankar Das

Non Executive Independent Director

35+ years of experience

He is an accomplished leader with more than 35 years of experience in the pharmaceutical industry. He has built and scaled businesses across India and other emerging markets. From 2014 to 2022, he was CEO and Director of Curatio Healthcare Private Limited, a domestic dermatology and cosmetic pharmaceutical company.

R&D Capabilities



API R&D Center



Location

Tanuku, Andhra Pradesh



DSIR and FDA (India)

Recognized

R&D Competencies

- New API development
- Cost optimization for existing molecules
- Troubleshooting plant problems
- Analytical development
- Process optimization
- Backward integration development

Immediate Focus Areas:

- Sertraline backward integration
- Metformin yield improvement
- New molecule commercialization's (4 annually)
- Patented molecules process development (post-FY29 focus area)



Formulations R&D Center



Location

Navi Mumbai, Maharashtra



DSIR and FDA (India)

Recognized

R&D Competencies

- Cost optimizations
- New product development
- Process technology development
- Development of Novel Platforms for Speciality Generics and Intellectual Property Rights (IPR)

R&D Capabilities



Process Optimization:

Optimization of synthesis routes for enhanced yields & lowering costs



Impurity Control:

Advanced analytical techniques aligned with ICH guidelines



Analytical Excellence:

DSIR-approved R&D facility with validated methods



Green Chemistry:

Integration of sustainable solvents, catalysis, and waste reduction efforts



Scale-Up Capability:

Lab to commercial with FTE team, integrated QC lab

Environment, Health & Safety

EHS at Wanbury


- **Best-in-class standards:** Committed to global EHS norms and strict regulatory compliance across all operations
- **Environmental focus:** Zero liquid discharge (ZLD) plants, advanced Effluent Treatment Plants (ETP), and continual investment in energy efficiency
- **Sustainable energy:** Upcoming 1.5 MW solar energy project at Satara, to meet 70% of Patalganga site's energy requirements captively through renewable energy
- **Safety culture:** Comprehensive training, systematic risk assessments (HAZOP), and robust emergency response systems at all sites
- **Community & workforce:** Prioritizing safety, public health, and sustainability for employees and local communities



02

Business Profile: API

Strategically Curated Product Portfolio	13
World-Class Manufacturing Infrastructure	14
Developed Market Focused Business Profile	15
Regulatory Approvals	16
Manufacturing Capabilities	17
Strategy & Way Forward	18
Safety First Culture	19



API: Strategically Curated Product Portfolio

Significant global market share in Top 3 products

Molecule	Therapeutic Category	Global Market (MT)	Estimated Market Share
Metformin	Antidiabetic	~75,000	~10%
Sertraline	Antidepressant	~680	~30%
Tramadol	Pain Management	~550	~11%

Existing portfolio – 6 molecules


- Metformin - Antidiabetic
- Sertraline - Antidepressant
- Tramadol - Pain Management
- Paroxetine - Antidepressant
- Mefenamic acid - Anti-inflammatory
- Diphenhydramine - Antihistamine

Recent portfolio addition – 1 molecule


- An Anaesthetic - Commercialised in Q4FY26
- 4 new additions each year beginning FY27

Note - Market Size, Market Share data as per Clarivate & Company Estimates

API - Revenue & Share



API Sales Breakdown



API: World-Class Manufacturing Infrastructure

Site 1: Tanuku, Andhra Pradesh



400 KL

Reactor Capacity



~70%

Revenue Contribution



450+

Headcount



18 Acres

Land Bank

Multi-Purpose Plant

Metformin, Sertraline,
Tramadol, Paroxetine,
Mefenamic Acid,
Diphenhydramine,
(upcoming
anaesthetic)

**Potential for future
brownfield CAPEX**

Site 2: Patalganga, Maharashtra



96 KL

Reactor Capacity



~30%

Revenue Contribution



250+

Headcount



2.3 Acres

Land Bank

Dedicated Plant

Metformin, Metformin DC

**Fully-occupied
at present**

Cumulative installed
reactor capacity:

500 KL

Future reactor capacity
potential at existing sites:

600 KL

API: Developed Market Focused Business Profile



Focused on regulated markets




Exporting to **50+** countries




Exporting to **4+** continents

Total Revenue Mix



■ Exports ■ Domestic



Map not to scale, only for illustration purpose.

API: Regulatory Credentials For Both Sites



US – FDA
Approval since **2000**

Last inspection **2024**



Europe – EDQM
Approval since **2007**

Last inspection **2014**



Brazil – ANVISA
Approval since **2024**

Last inspection **2024**



South Korea – KFDA
Approval since **2012**

Last inspection **2026**



Mexico – COFEPRIS
Approval since **2013**

Last inspection **2013**



WHO GMP
Approval since **2007**

Last inspection **2025**



EU Written
confirmation
Approval since **2013**

Last inspection **2025**

- **DMF/CEP Filings with Global Regulatory Authorities.**
- Planned filings **Quetiapine Fumarate (US & CEP), Ketamine HCl (CEP) & Paroxetine HCl (Brazil, Korea)**

	Approved	Pending	Total
USA	21	-	21
Europe	8	1	9
Brazil	1	5	6
South Korea	3	-	3
Mexico	-	-	-
ROW	31	-	31
Total			70

API: Manufacturing Capabilities

Chemistry Capabilities



- Azidation
- Bromination
- Cyanation
- Chiral Chemistry
- Optical Resolution
- Demethylation
- Grignard Reaction
- Sodium Metal Reactions
- Metal Hydride Reductions
- Friedel-Crafts Reactions
- Nitration
- Reductions
- Hydrogenation

Reaction Capabilities



- High Pressure Reactions
- High Vacuum Distillations
- Direct Compression (DC) Grade
- Manufacturing Different Polymorphisms
- Hydrated Molecules
- Handling Hygroscopic Products

System Capabilities



- Deployed SAP S4 HANA
- Dedicated software for Sales & Distribution functions
- Dedicated software for Fleet-on-Street
- Dedicated platforms used for sourcing & procurements
- Dedicated solutions for QC management

API: Strategy & Way Forward

Way Forward



Targeted expansion in regulated markets (US, EU, Brazil) – new & existing molecules



4 commercial launches of new molecules each year beginning FY27



Focus on a mix of:
a) High-value or
b) Large-volume + sizable market share molecules



Target patented molecules supply chain beyond FY29-30



Deploy backward integration selectively to optimize inputs cost & improve contribution margins



Product Selection Framework

Mid-Size Molecules

Small-to-Mid size molecules + Aim double-digit market share

Client Fit

Favour APIs requested by current marquee clientele

Margin Profile

Aim for ~50% gross margins

API: Safety First Culture





Certificate of Registration

This is to certify that

M/S.WANBURY LIMITED (DOCTORS ORGANIC CHEMICALS DIVISION)
KILLDALAPARKU, IRAGAVARAM (M), WEST GODAVARI DISTRICT, ANDHRA PRADESH, INDIA

has been independently assessed by QRO and is compliant with the requirement of

ISO 50001:2018
Energy Management Systems

For the following scope of activities:

M/S.WANBURY LIMITED IS AN INDIAN PHARMACEUTICAL COMPANY ENGAGED IN THE MANUFACTURING OF ACTIVE PHARMACEUTICAL INGREDIENTS (APIs), BY COMBINING QUALITY, SAFETY & ENVIRONMENTAL REQUIREMENTS INCLUDING ENERGY OPTIMIZATION WHILE MANUFACTURING. IT OPERATES IN BOTH DOMESTIC AND INTERNATIONAL MARKETS, WITH EXPORT TO OVER 40 COUNTRIES.

Date of Certification: 4th October 2023 2nd Surveillance Audit Due: 16th October 2027
1st Surveillance Audit Due: 18th September 2026 Certificate Expiry: 18th September 2028

Certificate Number: 305025100634EN





Certificate of Registration

This is to certify that

M/S.WANBURY LIMITED (DOCTORS ORGANIC CHEMICALS DIVISION)
KILLDALAPARKU, IRAGAVARAM (M), WEST GODAVARI DISTRICT, ANDHRA PRADESH, INDIA

has been independently assessed by QRO and is compliant with the requirement of

ISO 45001:2018
Occupational Health and Safety Management System

For the following scope of activities:

M/S.WANBURY LIMITED IS AN INDIAN PHARMACEUTICAL COMPANY ENGAGED IN THE MANUFACTURING OF ACTIVE PHARMACEUTICAL INGREDIENTS (APIs), BY COMBINING QUALITY, SAFETY & ENVIRONMENTAL REQUIREMENTS INCLUDING ENERGY OPTIMIZATION WHILE MANUFACTURING. IT OPERATES IN BOTH DOMESTIC AND INTERNATIONAL MARKETS, WITH EXPORT TO OVER 40 COUNTRIES.

Date of Certification: 18th September 2023 2nd Surveillance Audit Due: 18th September 2027
1st Surveillance Audit Due: 18th September 2026 Certificate Expiry: 18th September 2028

Certificate Number: 305025091971HS





Certificate of Registration

This is to certify that

M/S.WANBURY LIMITED (DOCTORS ORGANIC CHEMICALS DIVISION)
KILLDALAPARKU, IRAGAVARAM (M), WEST GODAVARI DISTRICT, ANDHRA PRADESH, INDIA

has been independently assessed by QRO and is compliant with the requirement of

ISO 14001:2015
Environmental Management System

For the following scope of activities:

M/S.WANBURY LIMITED IS AN INDIAN PHARMACEUTICAL COMPANY ENGAGED IN THE MANUFACTURING OF ACTIVE PHARMACEUTICAL INGREDIENTS (APIs), BY COMBINING QUALITY, SAFETY & ENVIRONMENTAL REQUIREMENTS INCLUDING ENERGY OPTIMIZATION WHILE MANUFACTURING. IT OPERATES IN BOTH DOMESTIC AND INTERNATIONAL MARKETS, WITH EXPORT TO OVER 40 COUNTRIES.

Date of Certification: 18th September 2023 2nd Surveillance Audit Due: 18th September 2027
1st Surveillance Audit Due: 18th September 2026 Certificate Expiry: 18th September 2028

Certificate Number: 305025091970E





NATIONAL SAFETY COUNCIL - MAHARASHTRA CHAPTER
MAHARASHTRA SAFETY AWARDS - 2023

This Certificate is presented to

M/s. Wanbury Ltd.
A-1, Parangipada, Tal. Khalapur, Dist. Raigad

for achieving

LOWEST ACCIDENT FREQUENCY RATE & LONGEST ACCIDENT FREE PERIOD

in

Paper, Sugar & Pharmaceuticals
Industrial Group

During: This Tenure Starting Day of September 2023





NATIONAL SAFETY COUNCIL - MAHARASHTRA CHAPTER
MAHARASHTRA SAFETY AWARDS - 2021

This Certificate is presented to

Wanbury Ltd.
A-1, Parangipada, Raigad

for achieving

NEAR ZERO PERFORMANCE IN INDUSTRIAL SAFETY DURING THE YEAR - 2021

in

Paper, Sugar & Pharmaceuticals
Industrial Group

During: This Tenure Starting Day of September 2020





NATIONAL SAFETY COUNCIL - MAHARASHTRA CHAPTER
MAHARASHTRA SAFETY AWARDS - 2024

This Certificate is presented to

Wanbury Ltd.
A-1, MIDC Industrial Area, Parangipada, Tal. Khalapur, Dist. Raigad

for achieving

LOWEST ACCIDENT FREQUENCY RATE & LONGEST ACCIDENT FREE PERIOD

in

Paper, Sugar & Pharmaceuticals
Industrial Group


During: This Tenure Starting Day of September 2023



03

Business Profile: Formulations

Re-Building Business	21
Brand Portfolio	22
Strategy & Way Forward	23



Formulations: Re-Building Business

Overview

- Formulations business journey commenced in 1995 with the acquisition of Wander Ltd, formerly a division of Sandoz
- Current portfolio is focused on therapeutics such as anti-cold & cough, anti-infective, anti-inflammatory, analgesic, antipyretic, orthopaedic and constipation medications, as well as protein supplements, multivitamins, and multimineral supplements
- Operating through a fully outsourced manufacturing model, enabling enhanced scalability and flexibility
- Strategic emphasis remains on building strong brands & distribution channels, driven by a dedicated business excellence team



10+
Brands

100%
Acute Therapy


300+
Field Force

30,000+
Doctors Engaged


17
C&F Agents

1,800+
Distributors

Formulations - Revenue & Share



Revenue Mix – Top Brands



Formulations: Brand Portfolio

Top brands

Coriminic®

Anti Cold & Cough



Chymonac™

Pain & Inflammation,
Muscular Spasm



RabiPlus™

Antacids & Anti-ulcerants



Senasof™

Herbal Laxative



Nurture®

Protein Supplement



ADTROL

Calcium Supplement -
Osteoporosis & Bone Health



WANBURY C RED

Nutritional Supplement



Zeva™

Multivitamin Supplement



Formulations: Strategy & Way Forward

Operational Objectives

1 Latest brand launch (FY25)
C RED (Iron Supplement)

2 Upcoming therapeutic launches

Paediatrics, Dermatology: Better right-to-win through existing brand equity with Paediatricians

Cardiology & Diabetes: Launching chronic & speciality products to improve productivity & add portfolio diversity

Speciality Segments: Building presence across GYN/PED/CP/ORTHO/SUR segments

3 Planned geographic expansion

Expansion into newer attractive regions

Increasing field force for existing regions

Strategic Way Forward



Leverage 3+ decades of heritage to re-build a scalable branded formulations franchise



Transition portfolio from acute therapeutics towards speciality and chronic segments through new launches



Geographical expansion in newer attractive markets



Achieve profitability break-even in FY26 through better scale & cost-management efforts



Deliver sustainable profitability FY27 onwards, through: Scaling top brands, launching new therapies, increasing front-line doctor engagement

04

Q4 & FY26 Earnings Update

Performance Highlights	25
Business Vertical Performance	26
P&L Snapshot	27
Management Commentary	28




Q4 & FY26 Performance Highlights

Revenue (in ₹ Crore)




(4%)

YOY GROWTH



8%

YOY GROWTH




EBITDA (in ₹ Crore)




(4%)

YOY GROWTH



35%

YOY GROWTH




PAT (in ₹ Crore)




7%

YOY GROWTH





117%

YOY GROWTH





Business Vertical Performance

API - Revenue (in ₹ Crore)



Formulations - Revenue (in ₹ Crore)



Q4 & FY26 P&L Snapshot

PARTICULARS (in ₹ Crore)	Q4FY25	Q3FY26	Q4FY26	YOY Change	QOQ Change	FY25	FY26	YOY Change
Revenue from Operations	172.00	162.45	164.58	1%	-4%	599.51	650.27	8%
Other Income	1.84	0.18	0.21	16%	-89%	3.49	0.94	-73%
COGS	83.25	68.80	65.30	-5%	-22%	294.47	276.51	-6%
Gross Profit	90.60	93.65	99.49	6%	10%	308.54	374.70	21%
Gross Margin (%)	52.7%	57.8%	60.4%	+269 BPS	+778 BPS	51.5%	57.6%	+616 BPS
Operating Expenses	58.05	66.96	69.42	4%	20%	228.62	267.00	17%
EBITDA	31.47	26.86	30.06	12%	-4%	79.91	107.69	35%
EBITDA Margin (%)	18.3%	16.5%	18.3%	173 BPS	-3 BPS	13.3%	16.6%	+323 BPS
Finance Cost	9.04	7.26	8.06	11%	-11%	36.95	29.98	-19%
Depreciation	3.37	3.74	3.23	-14%	-4%	13.41	14.31	7%
Profit before Tax	19.05	15.87	15.17	-4%	-20%	29.55	63.41	102%
Profit after Tax	20.26	15.76	21.70	38%	7%	30.53	66.13	117%
PAT Margins (%)	11.78%	9.7%	13.19%	+349 BPS	+141 BPS	5.1%	10.2%	+508 BPS
Basic EPS (in ₹)	6.18	4.52	7.26	61%	17%	9.32	20.55	120%

Management Commentary



Mr. Mohan Kumar Rayana
Promoter & Whole Time Director

“FY26 was an important year for Wanbury. We strengthened business fundamentals through operational efficiencies, debottlenecking, balance sheet improvement, and expansion of our API and formulations portfolio. Improved plant utilisation, enhanced product yields, and procurement efficiencies supported better EBITDA margins.


The fourth quarter saw a revenue decline due to the West Asia crisis impacting API export dispatches in March. This aside, we were on track to deliver growth on the back of new product launches in Q4.

A key milestone was the launch of our new Anaesthetic API with commercial dispatches beginning February 2026. Clearing the MFDS, Korea inspection with zero observations validates our compliance systems. We will continue our API growth journey in FY27 with recent launches and a strong pipeline, while the formulations business will operate from a stronger footing supported by new launches and an improved go-to-market strategy.”

05

Financial Profile


Key Performance Indicators	32
5Y P&L Snapshot	33
5Y Balance Sheet Snapshot	34
5Y Cash Flow Snapshot	35
Capital Markets Overview	36



Key Performance Indicators


Revenue from Operations

(in ₹ Crore)




Gross Profit & Gross Margins

(in ₹ Crore & in %)




EBITDA & EBITDA Margins

(in ₹ Crore & in %)




PAT & PAT Margins

(in ₹ Crore & in %)




Working Capital Days

(in Days)




ROCE

(in %)



ROE

(in %)



5Y P&L Snapshot

PARTICULARS (in ₹ Crore)	FY22	FY23	FY24	FY25	FY26
Revenue from Operations	511.2	499.7	575.7	599.51	650.26
Other Income	1.51	0.91	2.99	3.49	0.94
COGS	300.3	303.4	302.6	294.47	276.51
Gross Profit	212.4	197.1	276	308.53	374.70
Gross Margin (%)	42%	39%	48%	51%	58%
Operating Expenses	175.6	173	203	228.73	267.00
EBITDA	36.84	24.09	72.99	79.81	107.69
EBITDA Margin (%)	7%	5%	13%	13%	17%
Finance Cost	20.61	21.4	29.18	36.95	29.98
Depreciation	11.45	12.38	13.03	13.31	14.31
Exceptional Item	76.37	-0.6	-	-	3.60
Profit before Tax	81.13	-9.69	30.78	29.55	59.80
Profit after Tax	81.47	-10.4	30.4	30.53	66.13
PAT Margins (%)	16%	-2%	5%	5%	10%
Basic EPS (in ₹)	25.29	-3.18	9.29	9.32	20.55

5Y Balance Sheet Snapshot

PARTICULARS (in ₹ Crore)	FY22	FY23	FY24	FY25	FY26
Equity Share Capital					
Equity Share Capital	32.67	32.7	32.74	32.77	34.94
Other Equity	-30.48	-39.96	-4.8	26.5	109.51
Non-Current Liabilities					
Long Term Borrowings	-	-	82	160.29	147.15
Others	16.2	16.31	19.45	19.74	25.03
Current Liabilities					
Short Term Borrowings	67.02	64.14	27.27	12.94	68.30
Trade Payables	191.1	148.2	162.8	138.46	107.25
Advances from customers	14.92	9.27	2.78	2.97	
Others	59.54	71.58	20.93	20.25	
Total Equity and Liabilities	351	302.2	343.1	413.92	517.67
Non-Current Assets					
Tangible Assets	148.7	151.5	149	189.69	210.26
CWIP	2.35	1.61	3	5.38	25.42
Others	30.24	28.59	32.19	25.4	40.71
Current Assets					
Inventories	49.73	21.99	36.02	37.68	50.63
Trade Receivables	62.8	68.98	89.44	114.16	143.27
Current Investments	-	-	-	-	-
Cash & Bank Balances	25.27	3.89	5.9	12.83	7.63
Others	31.9	25.68	27.55	28.78	37.03
Total Assets	351	302.2	343.1	413.92	517.67


5Y Cash Flow Snapshot

PARTICULARS (in ₹ Crore)	FY22	FY23	FY24	FY25	FY26
Cash Flow from Operating Activities	37.56	19.8	4.02	26.1	31.53
Cash Flow from Investing Activities	0.59	-8.84	-16.62	-51.17	-56.40
Cash Flow from Financing Activities	-25.62	-31.99	14.55	25.73	22.42
Net Cash Flows	12.53	-21.03	1.95	0.66	-2.45
Cash at the Beginning of Year	9.96	22.49	1.45	3.4	4.06
Cash at the End of Year	22.49	1.46	3.4	4.06	1.61

Capital Markets Overview

Shareholding Pattern

(%)



Shareholding data as of 31st March 2026

Current Market Price

₹271

52 Week High/Low

₹321 / ₹162

Market Capitalization

₹948 Crore

No. of Shares Outstanding

3.49 Crore

NSE

WANBURY

BSE

524212

Market price data as of 22nd June 2026

Get in Touch

This document which has been prepared by Wanbury Limited ("Wanbury" or "the Company"), has been prepared solely for information purposes. This document has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Document. This Document may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Document is expressly excluded.

Certain matters discussed in this Document may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Document. The Company assumes no obligation to update any forward-looking information contained in this Document. Any forward-looking statements and projections made by third parties included in this Document are not adopted by the Company and the Company is not responsible for such third-party statements and projections.



Wanbury Limited

Vinod Verma

Chief Financial Officer

investor@wanbury.com /
investorrelations@wanbury.com

Jitendra J Gandhi

Company Secretary

cs@wanbury.com



TIL Advisors Private Limited

Sayam Pokharna

Investor Relations Advisor

sayam@theinvestmentlab.in



Adfactors PR

Hanishi Shah / Smit Shah

Investor Relations Advisor

Hanishi.shah@adfactorspr.com /
smit.shah@adfactorspr.com